Chongqing Genrix Biopharmaceutical Co Ltd

688443

Company Profile

  • Business description

    Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.

  • Contact

    No. 699, Maliu Avenue
    Area A, Building 2
    International Bio City
    Banan
    Chongqing401338
    CHN

    T: +86 2361758666

    http://www.genrixbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    743

Stocks News & Analysis

stocks

Alibaba fair value increases by 49%

Stronger-than-expected AI demand internationally and domestically.
stocks

Our fair value on ASX share falls by half

Downgrading our estimates due to lower growth.
stocks

A 5-Star US stock to buy with a near-5% yield

Undervalued by 23%, this cheap dividend stock is a top pick in its sector.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,148.5045.400.50%
CAC 407,880.8710.190.13%
DAX 4023,745.065.590.02%
Dow JONES (US)46,316.0768.780.15%
FTSE 1009,299.8415.010.16%
HKSE26,622.88494.681.89%
NASDAQ22,591.15107.090.48%
Nikkei 22545,043.75311.24-0.69%
NZX 50 Index13,140.367.800.06%
S&P 5006,661.2117.510.26%
S&P/ASX 2008,862.8052.100.59%
SSE Composite Index3,862.5334.430.90%

Market Movers